- ORIC Pharmaceuticals previously initiated the Himalayas-1 global Phase 3 registrational trial of rinzimetostat plus Bayer’s NUBEQA (darolutamide) in metastatic castration-resistant prostate cancer patients previously treated with abiraterone, aiming to enroll about 600 patients across 25 countries with radiographic progression-free survival as the primary endpoint.
- An interesting aspect of the update is that Bayer is supplying darolutamide at no cost while ORIC retains full global development and commercial rights to rinzimetostat.
- We’ll now examine how launching the Himalayas-1 Phase 3 trial in collaboration with Bayer shapes ORIC Pharmaceuticals’ investment narrative.
Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
What Is ORIC Pharmaceuticals' Investment Narrative?
For ORIC to make sense in a portfolio, you have to be comfortable owning a pre‑revenue biotech that is burning over US$100,000,000 a year and is not expected to be profitable in the next few years. The initiation of the Himalayas‑1 Phase 3 trial with Bayer’s darolutamide support sharpens the investment story around rinzimetostat and, in the near term, likely becomes the key catalyst that investors focus on, especially with the stock already up strongly year to date. Bayer supplying NUBEQA at no cost helps on trial economics, but it does not change the core risk that ORIC is still fully exposed to clinical, regulatory and financing uncertainty. With no revenue and ongoing losses, setbacks in Himalayas‑1 or delays across the pipeline would matter a lot more now.
However, one funding and dilution risk in particular stands out that investors should not ignore. The analysis detailed in our ORIC Pharmaceuticals valuation report hints at an inflated share price compared to its estimated value.Exploring Other Perspectives
Three Simply Wall St Community fair value views span roughly US$4.34 to US$43.40 per share, underscoring how differently people see ORIC’s prospects. Set against that spread, the newly launched Himalayas‑1 trial, and the company’s continuing cash burn, it is worth weighing how much binary clinical risk you are prepared to carry.
Explore 3 other fair value estimates on ORIC Pharmaceuticals - why the stock might be worth less than half the current price!
Decide For Yourself
Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your ORIC Pharmaceuticals research is our analysis highlighting 4 important warning signs that could impact your investment decision.
- Our free ORIC Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ORIC Pharmaceuticals' overall financial health at a glance.
Contemplating Other Strategies?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
- The latest GPUs need a type of rare earth metal called Dysprosium and there are only 29 companies in the world exploring or producing it. Find the list for free.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com